Therapy optimization of alfa-1-antitrypsin deficiency based on a pharmacokinetic approach Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005
Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA). Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Kinetics of plasma osteopontin during treatment in patients with pulmonary tuberculosis. A preliminary study Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008
The comparison study on the effects of high versus low flux membrane on pulmonary function tests in hemodialysis patients Source: Annual Congress 2012 - Predicting the future: the impact of reference values on a range of respiratory paramaters Year: 2012
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
LATE-BREAKING ABSTRACT: A new treatment combining valproate acid (VA) plus doxorubicin (D) for patients with refractory or recurrent malignant mesothelioma (MM): a phase II study Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours Year: 2009
Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
Comparison of the efficacy of two methods of treatment, standard and modified, on patients with Isoniazid resistant tuberculosis Source: Annual Congress 2007 - Difficult tuberculosis cases II Year: 2007
The effects of oral corticosteroid treatment (OCS) on sequential lung function tests in a cohort of patients with acute hypersensitivity pneumonitis (AHP) Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020
Measurement of serum total antioxidant status in patients with community acquired pneumonia: correlation with the severity of the disease Source: Eur Respir J 2002; 20: Suppl. 38, 283s Year: 2002
Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level Source: Annual Congress 2013 –COPD treatment and others Year: 2013
Age-Adjusted D-Dimer Cut Off: Could this prove cost-effective and safe for our Emergency Units?Authors:Mills M, Downey C , Townley S, Kasis A, Dutt T, Gautam M.Introduction:A D-dimer test result (conventionally up to 500 µg/L) is an important component of the diagnostic work-up for patients with suspected VTE, however, it is well known that D-Dimer levels rise with age. Although a negative D-Dimer in conjunction with a clinical probability score can be effective at excluding DVT/PE, studies have proposed that the use of an age-adjusted cut off can increase the number of patients excluded from further testing with a low likelihood of subsequent VTE.This study looked at unselected D-dimer requests from the Emergency department (ED) for patients with suspected DVT/PE to assess the potential impact of introducing age-adjusted D-dimer cut off limits. Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017
The effect of methylxanthine, corticosteroid, and N -acetylcystein on plasma oxidant/antioxidant levels in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 215s Year: 2001
The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002
Clinical effect of combined chemotherapy according to guidelines fro the treatment of pulmonary Mtcobacterium complex disease, including a follow-up study. Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
The role of serum rifampicin level on antituberculosis treatment outcome Source: Eur Respir J 2006; 28: Suppl. 50, 848s Year: 2006